SCHEMBL11029579

SCHEMBL11029579

NC(=O)c1ncc(Cc2c(Cl)cccc2Cl)cc1Nc1ccc(N2CCNCC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 1/20 0.47
▸ JAK1 P23458 1/20 0.47
▸ TYK2 P29597 1/20 0.47
▸ JAK3 P52333 1/20 0.47
▸ ALK Q9UM73 7/20 0.46
▸ MAPK8 P45983 2/20 0.46
▸ MAPK10 P53779 2/20 0.46
▸ STAT6 P42226 1/20 0.46
▸ MAPK9 P45984 1/20 0.46
▸ WEE1 P30291 2/20 0.44
▸ MT-CO2 P00403 1/20 0.44
▸ SLC2A1 P11166 1/20 0.43
▸ SYK P43405 1/20 0.42
▸ CDK4 P11802 1/20 0.42
▸ CCNA2 P20248 1/20 0.42
▸ CDK2 P24941 1/20 0.42
▸ CCND3 P30281 1/20 0.42
▸ CDK6 Q00534 1/20 0.42
▸ SIRT2 Q8IXJ6 1/20 0.42
▸ SIRT1 Q96EB6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11030740 0.89 SLC2A1 (0.55) JAK2JAK1TYK2JAK3ALK
SCHEMBL11029807 0.85 ALK (0.60) ALK
SCHEMBL11029039 0.83 JAK2 (0.52) JAK2JAK1TYK2JAK3ALK
SCHEMBL11027427 0.83 CCND3 (0.52) JAK2JAK1TYK2JAK3ALK
SCHEMBL11030660 0.80 ALK (0.55) JAK2ALK
SCHEMBL11033990 0.79 SLC2A1 (0.54) JAK2JAK1TYK2JAK3ALK
SCHEMBL11027579 0.78 SLC2A1 (0.49) JAK2JAK1TYK2JAK3ALK
SCHEMBL11951340 0.77 STAT6 (0.51) MAPK8MAPK10STAT6MAPK9SYK
SCHEMBL11029481 0.77 SLC2A1 (0.52) JAK2JAK3STAT6SLC2A1CDK2
SCHEMBL11325515 0.77 ALK (0.60) ALKMAPK8MAPK10MAPK9SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US claimed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP claimed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN claimed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO claimed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US claimed
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US disclosed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP disclosed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN disclosed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US disclosed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ALK, PKN2, ERBB2 JAK2 83/4885JAK1 248/4885TYK2 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback